- You are here:
- Home »
- Blog »
- breast cancer »
- Ivermectin, Breast Cancer & Research
Ivermectin, Breast Cancer & Research
Ivermectin, breast cancer & research. What does the science say? I am a long-term survivor of an incurable blood cancer called multiple myeloma. My oncologist told me that I was end-stage in September of 1997.
I underwent a non-FDA-approved therapy that put me in complete remission from my incurable cancer. I have only sympathy for cancer patients looking for therapies that work.
My goal is to make sure that breast cancer patients and survivors who consider ivermectin understand the risks and benefits of this therapy.
Good luck,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
I posted this video because it is an oncologist giving what I consider to be a fair, pros and cons, assessment of ivermectin as a cancer therapy.
Ivermectin to Treat Cancer? Get the FACTS
Research on ivermectin and breast cancer is mostly preclinical (cells/animals). It’s intriguing as a “drug repurposing” idea, but there’s no good clinical evidence yet that ivermectin treats breast cancer in people, and at least one breast cancer trial pathway has been withdrawn.
What the lab (preclinical) research shows
1) Direct anti-cancer effects in breast-cancer models
Several studies report that ivermectin can reduce breast-cancer cell growth and affect pathways linked with survival and spread:
- PAK1–AKT–mTOR / autophagy (cell + mouse models): ivermectin inhibited breast-cancer growth and induced “cytostatic” autophagy in preclinical work.
- Cancer stem-like cells: ivermectin preferentially inhibited breast cancer “stem-like” subpopulations and reduced expression of stemness genes in lab models.
- Apoptosis + reduced migration: ivermectin reduced proliferation and migration and induced apoptosis markers in breast-cancer cells in vitro (reported in a breast-cancer signaling paper referencing ivermectin as a PAK1 inhibitor).
2) Anti-metastasis / EMT and Wnt signaling
Wnt/β-catenin signaling is often implicated in invasion, EMT, and resistance phenotypes.
- In endocrine-resistant breast-cancer cell lines, ivermectin inhibited EMT-related behavior and Wnt-pathway features tied to invasion/metastasis.
- Separately, ivermectin has been shown to inhibit Wnt/β-catenin–related metastasis signaling in cancer models (not exclusively breast), which is often cited as a plausible mechanism for anti-motility effects.
- A mechanistic paper identifies TELO2 as a mammalian target linked to ivermectin’s Wnt/β-catenin repression (mechanism-focused, not breast-only).
3) Immune effects that could (in theory) help immunotherapy
A notable mouse-model study reported that ivermectin can promote immunogenic cancer cell death and increase T-cell infiltration into breast tumors, suggesting a possible rationale for combining ivermectin with checkpoint inhibitors.
What human research says (clinical evidence)
Human data in breast cancer are very limited and mostly in the form of trials/abstracts rather than definitive outcomes.
- An NCI-listed phase II trial of ivermectin + pembrolizumab for metastatic triple-negative breast cancer is shown as “withdrawn.”
- There are trial listings/abstract pages describing ivermectin combined with checkpoint inhibitors (e.g., balstilimab), but publicly available sources don’t (yet) establish clear efficacy outcomes in routine care.
Bottom line: Ivermectin is not an evidence-based breast cancer treatment at this time; it remains investigational.
A key practical issue: lab doses vs. achievable human exposure
Many breast-cancer cell studies use micromolar ivermectin concentrations. With typical approved oral dosing, reported peak blood levels are far lower (for example, one human PK paper reports ~50 ng/mL Cmax after 12 mg, which is in the tens of ng/mL range).
This “exposure gap” is one reason promising in-vitro effects often don’t translate into effective, safe cancer therapy.
Safety and interaction considerations (important if someone is considering off-label use)
Ivermectin is generally well-tolerated at antiparasitic doses, but adverse effects and drug–drug interactions matter—especially in oncology, where polypharmacy is common.
- FDA prescribing information (Stromectol) details warnings/adverse reactions.
- A review of human pharmacokinetics/interactions summarizes metabolism/interaction considerations.
- Post-marketing analyses discuss neurologic adverse events (rare but important), especially in certain contexts.
Clean PubMed links to key breast-cancer–relevant papers
- Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer: https://pubmed.ncbi.nlm.nih.gov/27657889/
- Ivermectin converts “cold” tumors “hot” and synergizes with checkpoint blockade in breast tumor models: https://pubmed.ncbi.nlm.nih.gov/33654922/
- PAK1/STAT3 pathway paper referencing ivermectin’s antiproliferative effects in breast-cancer cells: https://pubmed.ncbi.nlm.nih.gov/31641451/
- Ivermectin inhibits canine mammary tumor growth via WNT signaling (adjacent mammary evidence): https://pubmed.ncbi.nlm.nih.gov/31375107/
- Ivermectin inhibits tumor metastasis via Wnt/β-catenin/integrin β1/FAK axis (mechanistic metastasis paper): https://pubmed.ncbi.nlm.nih.gov/36381328/
Ivermectin, breast cancer & research Ivermectin, breast cancer & research